Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.36 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.33 |
| ▸ | FEN1 | P39748 | 2/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL155358 | 0.76 | KDM4E (0.52) | METAP2CYP2A6KDM4ECYP1A2ALDH1A1 | |
| SCHEMBL15512167 | 0.74 | CYP2A6 (0.49) | CYP2A6CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL4909130 | 0.73 | — | — | |
| SCHEMBL756428 | 0.73 | NISCH (0.34) | METAP2NISCHCYP2D6CYP19A1CYP2C9 | |
| SCHEMBL583848 | 0.73 | METAP2 (0.40) | METAP2CYP2A6NISCHCYP2D6CYP19A1 | |
| SCHEMBL4489657 | 0.72 | CYP2A6 (0.56) | METAP2CYP2A6CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL40492 | 0.72 | KDM4E (0.52) | CYP2A6KDM4ECYP1A2ALDH1A1HSD17B10 | |
| SCHEMBL28852322 | 0.70 | CCR1 (0.52) | METAP2CYP2A6PIM1ALDH1A1CYP3A4 | |
| SCHEMBL28852324 | 0.70 | CCR1 (0.55) | METAP2CYP2A6KDM4EALDH1A1 | |
| SCHEMBL1008860 | 0.69 | CYP1A2 (0.38) | METAP2NISCHCYP2D6CYP19A1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2696682-A2 | MIF INHIBITORS AND THEIR USES | Innovimmune Biotherapeutics, Inc. (US) | 2014-02-19 | — | — | EP | claimed |
| EP-2592933-A1 | MIF INHIBITORS AND THEIR USES | Gaweco, Anderson (US) | 2013-05-22 | — | — | EP | claimed |
| WO-2012142498-A2 | MIF INHIBITORS AND THEIR USES | INNOVIMMUNE BIOTHERAPEUTICS, INC. (US) | 2012-10-18 | — | — | WO | claimed |
| EP-2481736-A1 | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases | Deciphera Pharmaceuticals, LLC. (US) | 2012-08-01 | — | — | EP | claimed |
| US-8143293-B2 | disease caused by c-Abl kinase, c-Kit kinase, oncogenic forms, aberrant fusion proteins and polymorphs; 1-(3-t-butylisoxazol-5-yl)-3-(2-fluoro-4-(2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yloxy)phenyl)urea | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-03-27 | — | — | US | claimed |
| WO-2012019015-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-02-09 | — | — | WO | claimed |
| US-20120035150-A1 | MIF INHIBITORS AND THEIR USES | INNOV88 LLC | 2012-02-09 | — | — | US | claimed |
| WO-2012009649-A1 | MIF INHIBITORS AND THEIR USES | GAWECO ANDERSON (US) | 2012-01-19 | — | — | WO | claimed |
| US-20110189167-A1 | Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases | DECIPHERA PHARMACEUTICALS, LLC | 2011-08-04 | — | — | US | claimed |
| EP-2148677-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | Deciphera Pharmaceuticals, LLC. (US) | 2010-02-03 | — | — | EP | claimed |
| EP-1732906-A4 | 2-AMINOTHIAZOLE COMPOUNDS USEFUL AS ASPARTYL PROTEASE INHIBITORS | MERCK & CO INC (US) | 2007-11-21 | — | — | EP | claimed |
| EP-1836173-A2 | ANTI-INFLAMMATORY MEDICAMENTS | Deciphera Pharmaceuticals, LLC (US) | 2007-09-26 | — | — | EP | claimed |
| EP-1835934-A2 | ENZYME MODULATORS AND TREATMENTS | Deciphera Pharmaceuticals, LLC (US) | 2007-09-26 | — | — | EP | claimed |
| US-20070203147-A1 | 2-Aminothiazole Compounds Useful As Aspartyl Protease Inhibitors | MERCK SHARP & DOHME CORP. | 2007-08-30 | — | — | US | claimed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | claimed |
| EP-1732906-A1 | 2-AMINOTHIAZOLE COMPOUNDS USEFUL AS ASPARTYL PROTEASE INHIBITORS | Merck & Co., Inc. (US) | 2006-12-20 | — | — | EP | claimed |
| WO-2006081034-A2 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2006-08-03 | — | — | WO | claimed |
| WO-2006071940-A2 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2006-07-06 | — | — | WO | claimed |
| WO-2005097767-A1 | 2-AMINOTHIAZOLE COMPOUNDS USEFUL AS ASPARTYL PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2005-10-20 | — | — | WO | claimed |
| US-6593344-B1 | These substances have especially high cytostatic activities and pronounced immunosuppressive properties which make them suitable for therapeutic treatment in broad tumor spectrum and autoimmune diseases | KLINGE PHARMA GMBH (DE) | 2003-07-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203147-A1 | 2-Aminothiazole Compounds Useful As Aspartyl Protease Inhibitors | BACE2, BACE1, APP | METAP2 66/4885CYP2A6 1325/4885NISCH 3244/4885 |
| US-20120035150-A1 | MIF INHIBITORS AND THEIR USES | MIF, SERPINB1, HMGB2 | METAP2 148/4885CYP2A6 3091/4885NISCH 4514/4885 |
| US-20110189167-A1 | Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases | MCL1, NRAS, ABL1 | METAP2 2736/4885CYP2A6 4445/4885NISCH 3537/4885 |
| US-20070078121-A1 | Enzyme modulators and treatments | ABL1, ABL2, LCK | METAP2 1072/4885CYP2A6 2233/4885NISCH 4374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.